Cwm LLC boosted its position in shares of Encompass Health Co. (NYSE:EHC – Free Report) by 27.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,164 shares of the company’s stock after purchasing an additional 1,776 shares during the period. Cwm LLC’s holdings in Encompass Health were worth $789,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in EHC. Magnetar Financial LLC grew its holdings in Encompass Health by 1,176.6% during the 2nd quarter. Magnetar Financial LLC now owns 744,836 shares of the company’s stock valued at $63,899,000 after purchasing an additional 814,018 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in Encompass Health by 2,302.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 603,558 shares of the company’s stock valued at $51,780,000 after purchasing an additional 578,438 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Encompass Health by 614.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 540,519 shares of the company’s stock valued at $44,637,000 after purchasing an additional 464,897 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Encompass Health by 379.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 578,349 shares of the company’s stock valued at $38,587,000 after purchasing an additional 457,796 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Encompass Health by 4.7% during the 4th quarter. Vanguard Group Inc. now owns 9,997,034 shares of the company’s stock valued at $667,002,000 after purchasing an additional 450,081 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on EHC shares. KeyCorp began coverage on shares of Encompass Health in a report on Friday, October 11th. They set an “overweight” rating and a $115.00 price target for the company. Royal Bank of Canada increased their price objective on shares of Encompass Health from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Thursday, September 26th. Truist Financial increased their price objective on shares of Encompass Health from $104.00 to $108.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Leerink Partnrs upgraded shares of Encompass Health to a “strong-buy” rating in a research note on Wednesday, July 10th. Finally, UBS Group increased their price objective on shares of Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Eight research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Encompass Health presently has an average rating of “Buy” and an average price target of $104.67.
Encompass Health Trading Up 0.3 %
Encompass Health stock opened at $97.19 on Friday. The firm’s 50-day moving average is $92.85 and its 200-day moving average is $87.77. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.35 and a current ratio of 1.35. Encompass Health Co. has a 1 year low of $57.55 and a 1 year high of $98.74. The company has a market cap of $9.79 billion, a P/E ratio of 26.27, a PEG ratio of 1.43 and a beta of 0.88.
Encompass Health (NYSE:EHC – Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.10. Encompass Health had a net margin of 7.88% and a return on equity of 17.83%. The company had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.30 billion. During the same period last year, the firm posted $0.95 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. On average, equities analysts expect that Encompass Health Co. will post 4.18 earnings per share for the current year.
Encompass Health Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be issued a $0.17 dividend. The ex-dividend date is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.70%. Encompass Health’s dividend payout ratio (DPR) is presently 18.38%.
Encompass Health declared that its board has approved a stock buyback plan on Wednesday, July 24th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 5.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its shares are undervalued.
Insider Buying and Selling
In related news, CFO Douglas E. Coltharp sold 12,260 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $86.34, for a total value of $1,058,528.40. Following the sale, the chief financial officer now owns 136,227 shares of the company’s stock, valued at $11,761,839.18. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.10% of the company’s stock.
Encompass Health Profile
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
See Also
- Five stocks we like better than Encompass Health
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Survey Reveals: America’s Most Coveted Businesses in 2024
- 5 discounted opportunities for dividend growth investors
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Canadian Penny Stocks: Can They Make You Rich?
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.